Oral antidiabetic agents are drug classes that lower blood glucose in type 2 diabetes mellitus by acting on one of three mechanisms — stimulating pancreatic insulin secretion, suppressing hepatic gluconeogenesis, or enhancing peripheral glucose uptake — and their applicability is bounded by the requirement of residual beta-cell function, which is why they are ineffective in insulin-dependent type 1 diabetes. Because these drugs act on a continuously varying physiologic parameter, the therapeutic principle is one of dose-response overshoot: agents that increase circulating insulin carry hypoglycemia as a mechanism-linked adverse effect, while agents acting outside the insulin-secretion pathway carry metabolic risks instead. The topic belongs to endocrine pharmacology within nursing pharmacotherapeutics and illustrates the parent discipline's rule that the site of action determines both the indication boundary and the characteristic toxicity.
Oral antidiabetic agents are drug classes that lower blood glucose in type 2 diabetes mellitus by acting on one of three mechanisms — stimulating pancreatic insulin secretion, suppressing hepatic glu…